German Minister clashes with pharma

18 October 2001

German Economics Minister Werner Muller's proposed alternative to HealthMinister Ulla Schmidt's drug costs savings package has been attacked by the drug industry group, the BPI. He had said that Ms Schmidt's planned 4% drug price cut should be replaced by a comparable discount for the health funds (Marketletters passim) but, after talks between the two sides, the BPI said the impact of either proposal would be negative.

Mr Muller is now expected to withdraw from this hotspot and leave it to the parliamentary committee of his party, the Social Democrats who, with the Greens, generally back the Schmidt package, which will relieve the funds of some 2 billion Deutschemarks ($929.2 million) of spending. Social Democrat parliamentary panel chairman Peter Struck has defended making drugmakers cut prices and higher discounts for pharmacies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight